Coya Therapeutics

Impact: Coya Therapeutics is facing multiple class action lawsuits for allegedly misleading investors about the safety of its Duchenne muscular dystrophy gene therapy, Delandistrogene moxeparvovec, after several patient deaths due to acute liver failure. This has led to significant stock price declines and regulatory scrutiny.

Impact: Coya Therapeutics is the biopharmaceutical company developing Lonvoguran ziclumeran, a CRISPR-based gene editing therapy for hereditary angioedema. The presentation of Phase 3 HAELO clinical trial data is a significant milestone for the company, potentially leading to a one-time treatment for HAE.

Impact: Coya Therapeutics Inc. is being acquired by ClinActiv Holdings Inc. for $0.80 per share, leading to its delisting from the Toronto Stock Exchange and ceasing to be a reporting issuer.

Impact: Coya Therapeutics will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026, providing an opportunity to present its pipeline and strategy to investors and potentially increase its visibility and investor interest.

Impact: Coya Therapeutics is a publicly traded company presenting at the conference, seeking to engage with investors and highlight its advancements.

Impact: Biotech company that had public disagreements with FDA. Regulatory changes could impact its product approvals.

Impact: Dieter Weinand currently serves on the board of Coya Therapeutics, and will reduce his board seats to focus on his role at Evotec.